12.23.25 -- STREAM Edition: Engineering B Cells With Immusoft's Sean Ainsworth

Explore how a vertical wheel bioreactor enables efficient, linear scale-up of PSC cultures while maintaining quality, viability, and pluripotency for advanced cell therapy manufacturing.

Discover smarter solutions with the new Analytics Knowledge Hub that provides articles, webinars, e-books, and infographics designed to enhance and streamline your bioprocess workflow.

 

In this segment from the Cell & Gene Live digital event, our panelists share some horror stories on mistakes they’ve witnessed when bringing stem-cell derived therapies to patients, as well as their thoughts on how to avoid such failures.

The high cost of producing new cell and gene therapies is a large issue facing the industry. After launching Kymriah and Yescarta, Novartis’ price tags were $475,000 and $375,000, respectively. Advancements in manufacturing are driving costs down, but not at the required pace.

Transform your approach to processing fresh or thawed cellular products with the S-Wash application. This advanced solution, designed to work seamlessly with the Sefia™ system, automates the concentration, washing, and medium exchange steps efficiently.

Take a look behind the scenes and uncover what drives the team every day. Hear firsthand about the commitment to patients from scientists and specialists supporting clients around the world. Assimilate how collaboration comes together to advance life-changing therapies.

On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell therapies offer a better, more patient-friendly administration for lysosomal storage diseases currently treated with enzyme replacement therapies.